The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Josep M Llovet
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Can-Fite BioPharma; Celsion; Eisai; Exelis; Fortress Biotech; Glycotest; Ipsen; Lilly; Merck; Midatech Pharma; Navigant Consulting; Nucleix
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Ipsen
 
Masahiro Kobayashi
Honoraria - Abbvie; EA Pharma; Eisai; Gilead Sciences; Nippon Kayaku; Sumitomo Group
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bayer Yakuhin; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Marc Pracht
Travel, Accommodations, Expenses - MSD
 
Max W. Sung
Consulting or Advisory Role - Bayer; Eisai; Exelixis
 
Ari David Baron
Speakers' Bureau - Abbvie; Amgen; Bristol-Myers Squibb; Eisai; Johnson & Johnson; Lilly; Merck
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Ono Pharmaceutical; Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Tim Meyer
Consulting or Advisory Role - Beigene; Bristol-Myers Squibb; BTG; Eisai; Ipsen; MSD; Roche
Research Funding - Bayer (Inst); BTG (Inst); Ipsen (Inst)
 
Takuji Okusaka
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Eisai; Nihon Servier; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Baxter (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
 
Hiromitsu Kumada
Honoraria - Abbvie; Eisai; Gilead Sciences; MSD; Sumitomo Dainippon
 
Shuichi Kaneko
Honoraria - Abbvie; ASKA Pharmaceutical; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; EA Pharma; EI Dupont; Eisai; Gilead Sciences; Kowa; Lilly; Mitsubishi Tanabe Pharma; Miyarisan Pharmaceutical; Mochida Pharmaceutical Co. Ltd.; MSD; Mylan; Otsuka; Sumitomo Group; Sysmex; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda
Consulting or Advisory Role - Bayer; Hokkoku Bank; Kowa
Research Funding - Abbott Vascular Japan; Abbvie; Alexion Pharmaceuticals; ASKA Pharmaceutical; Astellas Pharma; Bayer; Biotronik International; Boston Scientific; Bristol-Myers Squibb; Central Medical; Daiichi Sankyo; EA Pharma; Eisai; Gilead Sciences; Japan Lifeline; Kataoka; Kowa; Kyowa Kirin; Lilly; Medtronic; Mitsubishi Tanabe Pharma; MSD; Mylan; Nihon Medi-Physics; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Novo Nordisk; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Sanwa Kagaku Kenkyusho; Shionogi; St. Jude Medical Japan; Sumitomo Group; Taiho Pharmaceutical; Taisho Toyama Pharma; Takeda; Teijin Pharma; TERUMO; Tomiki Medical Instruments; Zeon Medical; Zeria Pharmaceutical
 
Taisuke Hoshi
Employment - Eisai
Stock and Other Ownership Interests - Eisai
Patents, Royalties, Other Intellectual Property - Eisai
 
Kenichi Saito
Employment - Eisai
Patents, Royalties, Other Intellectual Property - Applying patent for pharmaceutical composition
 
Shuyu D Li
Employment - Eisai; Luye Pharma (I); Sema4; Symphogen (I); Taiho Oncology (I)
 
Yasuhiro Funahashi
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Yukinori Minoshima
Employment - Eisai
Stock and Other Ownership Interests - Eisai
 
Leonid Dubrovsky
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer